Ling Ni

Dr. Ling Ni

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2018 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
LNLing Ni
Ling Ni
JLJian Lu
Jian Lu
Immune system can recognize self vs transformed self. That is why cancer immunotherapy achieves notable benefits in a wide variety of cancers. Recently, several papers reported that immune checkpoint blockade therapy led to upregulation of IFNγ and in turn clearance of tumor cells. In this review, we conducted an extensive literature search of recent 5‐year studies about the roles of IFNγ signaling in both tumor immune surveillance and immune evasion. In addition to well‐known functions, IFNγ signaling also induces tumor ischemia and homeostasis program, resulting in tumor clearance and tumor escape, respectively. The yin and the yang of IFNγ signaling are summarized. Thus, this review helps us to comprehensively understand the roles of IFNγ in tumor immunity, which contributes to better design and management of clinical immunotherapy approaches.

7 July 2017 in Cell Research
Verified
Journal Article
Closed access
PDF file
YLYoung-Hee Lee
Young-Hee Lee
NMNatalia Martin-Orozco
Natalia Martin-Orozco
PZPeilin Zheng
Peilin Zheng
JLJing Li
Jing Li
PZPeng Zhang
Peng Zhang
CDChen Dong
Chen Dong

1 July 2017 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
LNLing Ni
Ling Ni
CDChen Dong
Chen Dong
T cells are the main effector cells in immune response against tumors. The activation of T cells is regulated by the innate immune system through positive and negative costimulatory molecules. Targeting immune checkpoint regulators such as programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) and CTL antigen 4 (CTLA-4) has achieved notable benefit in a variety of cancers, which leads to multiple clinical trials with antibodies targeting the other related B7/CD28 family members. Recently, five new B7 family ligands, B7-H3, B7-H4, B7-H5, B7-H6, and B7-H7, were identified. Here we review recent understanding of new B7 family checkpoint molecules as they have come to the front of cancer research with the concept that tumor cells exploit them to escape immune surveillance. The aim of this article is to address the structure and expression of the new B7 family molecules as well as their roles in controlling and suppressing immune responses of T cells as well as NK cells. We also discuss clinical significance and contribution of these checkpoint expressions in human cancers. Mol Cancer Ther; 16(7); 1203–11. ©2017 AACR.

1 April 2018 in Immunity
Verified
Journal Article
Closed access
JLJing Li
Jing Li
YLYounghee Lee
Younghee Lee
YLYanjian Li
Yanjian Li
YJYu Jiang
Yu Jiang
HLHuiping Lu
Huiping Lu
CDChen Dong
Chen Dong

23 January 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
QSQinli Sun
Qinli Sun
XZXiaohong Zhao
Xiaohong Zhao
RLRuifeng Li
Ruifeng Li
DLDingfeng Liu
Dingfeng Liu
BPBirui Pan
Birui Pan
CDChen Dong
Chen Dong
In cancer, persistent antigens drive CD8+ T cell differentiation into exhausted progenitor (Texprog) and terminally exhausted (Texterm) cells. However, how the extrinsic and intrinsic regulatory mechanisms cooperate during this process still remains not well understood. Here, we found that STAT3 signaling plays essential roles in promoting intratumor Texterm cell development by enhancing their effector functions and survival, which results in better tumor control. In tumor microenvironments, STAT3 is predominantly activated by IL-10 and IL-21, but not IL-6. Besides, STAT3 also plays critical roles in the development and function of terminally differentiated effector CD8+ T cells in acute infection. Mechanistically, STAT3 transcriptionally promotes the expression of effector function-related genes, while it suppresses those expressed by the progenitor Tex subset. Moreover, STAT3 functions in collaboration with BATF and IRF4 to mediate chromatin activation at the effector gene loci. Thus, we have elucidated the roles of STAT3 signaling in terminally differentiated CD8+ T cell development, especially in cancer, which benefits the development of more effective immunotherapies against tumors.

1 April 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
SOSangKon Oh
SangKon Oh
LPLiyanage P. Perera
Liyanage P. Perera
MTMasaki Terabe
Masaki Terabe
LNLing Ni
Ling Ni
TWThomas A. Waldmann
Thomas A. Waldmann
JBJay A Berzofsky
Jay A Berzofsky
CD4 + helper T cells contribute to the induction and maintenance of antigen-specific CD8 + T cells. Their absence results in short-lived antigen-specific CD8 + T cells and defective secondary CD8 + T cell responses because of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis. Here, we show that IL-15 codelivered with vaccines can overcome CD4 + T cell deficiency for promoting longevity of antigen-specific CD8 + T cells and avoidance of TRAIL-mediated apoptosis. In both priming and secondary responses, IL-15 down-regulates proapoptotic Bax, an intermediate in TRAIL-mediated apoptosis, and increases anti-apoptotic Bcl-X L in CD8 + T cells. Thus, IL-15 is sufficient to mimic CD4 + T cell help. Antigen-specific CD4 + T cells induce dendritic cells (DCs) to produce IL-15. IL-15 is also necessary for optimal help, because helper cells do not deliver effective help through IL-15 −/− DCs. Therefore, IL-15 codelivered with vaccines can overcome CD4 + helper T cell deficiency for induction of functionally efficient CD8 + T cells and maintenance of CD8 + cytotoxic T lymphocytes (CTLs), and IL-15 is probably one of the natural mediators of help. These findings suggest new vaccine strategies against infections and cancers, especially in individuals with CD4-deficiency.